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Abstract
Background: As the amount of data from genome wide association studies grows dramatically, many interesting scientific
questions require imputation to combine or expand datasets. However, there are two situations for which imputation has
been problematic: (1) polymorphisms with low minor allele frequency (MAF), and (2) datasets where subjects are genotyped
on different platforms. Traditional measures of imputation cannot effectively address these problems.
Methodology/Principal Findings: We introduce a new statistic, the imputation quality score (IQS). In order to differentiate
between well-imputed and poorly-imputed single nucleotide polymorphisms (SNPs), IQS adjusts the concordance between
imputed and genotyped SNPs for chance. We first evaluated IQS in relation to minor allele frequency. Using a sample of
subjects genotyped on the Illumina 1 M array, we extracted those SNPs that were also on the Illumina 550 K array and
imputed them to the full set of the 1 M SNPs. As expected, the average IQS value drops dramatically with a decrease in
minor allele frequency, indicating that IQS appropriately adjusts for minor allele frequency. We then evaluated whether IQS
can filter poorly-imputed SNPs in situations where cases and controls are genotyped on different platforms. Randomly
dividing the data into ‘‘cases’’ and ‘‘controls’’, we extracted the Illumina 550 K SNPs from the cases and imputed the
remaining Illumina 1 M SNPs. The initial Q-Q plot for the test of association between cases and controls was grossly
distorted (l= 1.15) and had 4016 false positives, reflecting imputation error. After filtering out SNPs with IQS,0.9, the Q-Q
plot was acceptable and there were no longer false positives. We then evaluated the robustness of IQS computed
independently on the two halves of the data. In both European Americans and African Americans the correlation was.0.99
demonstrating that a database of IQS values from common imputations could be used as an effective filter to combine data
genotyped on different platforms.
Conclusions/Significance: IQS effectively differentiates well-imputed and poorly-imputed SNPs. It is particularly useful for
SNPs with low minor allele frequency and when datasets are genotyped on different platforms.
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Introduction
Genome-wide association studies (GWAS) represent a power-
ful approach to the identification of genetic variants involved in
common human diseases[1]. GWAS use commercial SNP micro-
arrays to genotype large numbers of genetic markers. However,
SNP microarrays currently can only genotype up to one million of
the 9–10 million common SNPs in the assembled human genome
[2]. In addition, for a typical case-control design, several thousand
cases and several thousand controls may be needed for adequate
power to detect associations[3]. With little cost, imputation can
boost power both by increasing SNP coverage and by combining
samples from similar studies. Based on haplotypes from the
International HapMap project[4], imputation infers untyped
variants from known genotypes. The inference uses one of several
model-based methods, and the resulting imputed SNPs can be
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tested for association with a phenotype [5]. The power of this
method has been demonstrated in the literature where several
groups have found novel causal genes [6,7,8,9].
There are two situations where researchers avoid imputation due
to increased error in imputation: (1) SNPs with minor allele
frequency less than 1% [1,6,10], and (2) association studies where
cases and controls are genotyped on different platforms. Imputation
accuracy, calculated for each SNP as the proportion of genotypes
correctly classified, is the gold standard for evaluating the quality of
imputation. Unfortunately, it is an inadequate filter in both of these
circumstances. For the majority of SNPs, imputation programs such
as IMPUTE [5], MACH[10], and BEAGLE[11], have very high
imputation accuracy [5,11,12,13]. However, the use of imputation
accuracy in low frequency SNPs to evaluate imputation quality can
be misleading. When the minor allele frequency of a SNP is less than
5%, a program could randomly assign the two alleles to the sample
only using the minor allele frequency and achieve more than 90%
accuracy. Although SNPs with low minor allele frequencies
(MAF,5%) are referred to as uncommon SNPs, they represent
more than 30% of SNPs in the HapMap Phase II CEU population,
and this proportion is even higher in African populations[2]. This
problem assessing imputation accuracy in lower frequency SNPs
means that a large part of the genome will not be adequately
interrogated using imputation.
The second problematic situation for imputation is where cases
and controls are genotyped on different platforms. This is
problematic because imputation error can vary between cases
and controls, causing increased rates of false positives in
association studies. There is no known method for effectively
filtering the poorly imputed SNPs from the well imputed SNPs on
different platforms. Although this situation has been avoided by
researchers, it is an important application. Large studies such as
Wellcome Trust and the NIMH GAIN samples use common
controls that could be used in other studies to gain power [1,14].
But, if the primary datasets were genotyped on a different
platform, imputation is necessary.
In order to assess the reliability of imputation with an emphasis
on the less common SNPs and an interest in evaluating data
imputed from different platforms, we introduce a new statistic, the
imputation quality score (IQS). Partly motivated by Cohen’s
statistic Kappa to quantify rater agreement[15], IQS takes chance
agreement into account and thus controls for allele frequencies. In
this paper, we introduce IQS, demonstrate its value in situations of
low minor allele frequencies, and demonstrate how it can be used
to improve the type I error rate when cases and controls are
genotyped on different platforms.
Materials and Methods
Ethics statement
De-identified data from the Study of Addiction: Genetics and
Environment (SAGE) were analyzed for the research reported in
this manuscript. SAGE consists of existing data from three genetic
studies of addiction: the Collaborative Study on the Genetics of
Alcoholism (COGA), the Collaborative Genetic Study of Nicotine
Dependence (COGEND), and the Family Study of Cocaine
Dependence (FSCD). All participants in COGA, COGEND and
FSCD provided written informed consent for genetic studies and
agreed to share their DNA and phenotypic information for
research purposes. The institutional review boards at all data
collection sites granted approval for data collected from COGA,
COGEND and FSCD to be used for the Study of Addiction:
Genetics and Environment. Specifically, approval was obtained
from the Washington University Human Research Protection
Office (for COGA, COGEND and FSCD), the State University of
New York Downstate Medical Center Institutional Review Board
(COGA), the University of Connecticut Health Center Human
Subjects Protection Office (COGA), the Indiana University
Research Compliance Administration (COGA), the University of
California, San Diego Human Research Protections Program
(COGA), the Howard University Institutional Review Board
(COGA), The University of Iowa Human Subjects Office
(COGA), and the Henry Ford Health System Institutional Review
Board (COGEND). The second dataset was obtained from the
National Institute of Mental Health Center for Collaborative
Genetic Studies on Mental Disorders (http://www.nimhgenetics.
org/) and was also de-identified.
Methods
The computation of IQS requires the posterior probabilities of
AA, AB and BB as output by the imputation program. For one
SNP genotyped on N individuals, the probabilities can be readily
tabulated into a 363 table where each cell, nij, represents the
number of individuals with true genotype i and imputed genotype j
(Table 1). Note, in this scenario, nij may not be an integer due to
imputation probabilities being reported rather than imputed
genotypes.
We define the observed proportion of agreement (Po) as:
Po~
P
inii
n::
The observed proportion of agreement can be used to evaluate
imputation reliability. But, like imputation accuracy and average
maximum posterior probability, it can overestimate reliability for
uncommon SNPs because it is not adjusted for ‘‘chance’’
agreement.
IQS adjusts for allele frequency by subtracting ‘‘chance’’
agreement from the ‘‘observed’’ agreement. Similar to Po,
‘‘chance’’ agreement (Pc) is computed as the sum of the products
of marginal frequencies that would occur if genotypes are called at
random using the same marginal rates:
Pc~
P
ini:n:i
n::2
IQS is then computed by subtracting the chance agreement
from the observed agreement and dividing by the maximum
possible value of the numerator. The value of one indicates a
Table 1. Marginal cross classification of the genotypes used
for the computation of IQS.
True genotypes
Imputed
Genotypes AA AB BB Total
AA n11 n12 n13 n1.
AB n21 n22 n23 n2.
BB n31 n32 n33 n3.
Total n.1 n.2 n.3 n..
IQS adjusts for minor allele frequency by comparing observed frequencies to
expected frequencies.
doi:10.1371/journal.pone.0009697.t001
Imputation Quality Score
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perfect match, and negative values indicate that the imputation
program performed worse than chance.
IQS~
Po{Pc
1{Pc
In addition, the calculation of IQS can be expanded to evaluate
non-random error. When cases and controls are genotyped on
different platforms (e.g., cases genotyped on the Affymetrix array
and controls genotyped on the Illumina array), some SNPs are not
genotyped in either array but are imputed from their respective
arrays. This imposes non-random errors on the imputed
genotypes. In particular, if we combine these imputed genotypes
together, it will inflate false positive rates. IQS can take this into
account by incorporating marginal frequencies into the calcula-
tion. For instance, if imputation from the Illumina array reports
that for a particular SNP, the probabilities of AA, AB and BB are
a1, a2, a3, and imputation from the Affymetrix array reports that
the probabilities for the three genotypes are b1, b2, b3, then nij in the
calculation of Po becomes
nij~aibj
In this scenario, IQS provides a useful criterion to exclude
unacceptable SNPs imputed from different sources.
Data and imputation
The first dataset was collected as part of SAGE, one study in the
Gene Environment Association (GENEVA) project (http://
genevastudy.org/). Samples were genotyped on the Illumina
Human 1 M array at the Center for Inherited Disease Research
(CIDR) at Johns Hopkins University. The Illumina 1 M array has
a total of 1,049,008 probes as SNP assays. All SNPs with a
genotype call rate ,98% were removed, as were SNPs with
a Hardy-Weinberg exact p value ,161024. Additional data
cleaning procedures were applied to ensure the highest possible
data quality, including using HapMap controls, detection of
gender and chromosomal anomalies, hidden relatedness, popula-
tion structure, batch effects, Mendelian error detection, and
duplication error detection[16]. The composition of the remaining
project samples in terms of self-identified ethnicity is 2597
European Americans and 1264 African Americans, confirmed
by principal component analysis. Among the 1,049,008 SNPs,
948,658 SNPs (90%) passed data cleaning procedures.
The second dataset consists of controls from the National
Institute of Mental Health Center for Collaborative Genetic
Studies on Mental Disorders (http://www.nimhgenetics.org/). A
total of 418 subjects (controls) were genotyped using both the
Affymetrix GeneChip Mapping 500 K Array Set and the Illumina
HumanHap 550 K Array set and passed all cleaning procedures.
All individuals in this study were European Americans with no
evidence of heterogeneity, verified by principal component
analysis[17]. All SNPs with a genotype call rate ,95% were
removed, as well as SNPs with a Hardy-Weinberg exact p value
,161025. After quality control, 447,250 autosomal SNPs were
retained from the Affymetrix 500 K array, and 527,095 autosomal
SNPs were retained from the Illumina 550 K array.
Imputation from each array to Hapmap SNPs was done by the
program IMPUTE (https://mathgen.stats.ox.ac.uk/impute/impute_
v0.5.html) [5]. European Americans were imputed using the CEU
reference panel (HapMap release 22 - NCBI Build 36 dbSNP b126).
African Americans were imputed separately using the YRI
reference panel (HapMap release 22 - NCBI Build 36 dbSNP
b126). We omitted sex chromosomes in this study because of the
complication of imputation on these chromosomes. The Illumina
1 M array contains a small number of strand-ambiguous A/T C/G
SNPs. Although Illumina provides strand information about those
SNPs, we still found a few inconsistencies compared with the
reference panel. In order to make sure that all SNPs were reported
on the same strand, all strand-ambiguous A/T and C/G SNPs
(5583 in total, 0.5% of all Illumina 1 M SNPs) were excluded from
the comparison.
Imputation efficiency is calculated as the proportion of geno-
types that had a maximum posterior probability greater than 0.9,
as recommended by IMPUTE.
Association tests were done by the program SNPTEST with the
‘‘-proper’’ option[5]. With this option, SNPTEST runs a logistic
regression based on the probability of genotype rather than
dichotomous genotype, allowing the uncertainty of the imputation
to be factored into the consideration [18].
Statistical estimates of imputation quality
Both IQS and imputation accuracy compare true genotypes to
imputed genotypes. Given that imputation is designed to infer
unknown genotypes, one purpose of this paper was to use IQS to
evaluate statistics that measure the quality of imputation without
knowing the true genotype. The two statistics most commonly
used for this purpose are the variance ratio (rsq_hat in
MACH)[10] and the imputed information score (PROPER_INFO
in SNPTEST) [5]. The variance ratio for a particular SNP is a
ratio of the empirically observed variance (based on the
imputation) to the expected binomial variance p(1-p), where p is
the minor allele frequency[18]. As the amount of information
available to impute the SNP decreases, the empirically observed
variance decreases and the variance ratio approaches zero. The
product of the variance ratio and sample size defines the ‘effective
sample size’. Similarly, the imputed information score is a measure
of genotype information content, which is related to the effective
sample size (power) for the genetic effect being estimated [1,5,18].
Although computed using a different approach, the information
score is analogous to the variance ratio. For example, a SNP with
an imputed information score of 0.75 indicates that the imputed
SNP genotypes are equivalent to a dataset with 75% of the full
sample size with precisely known genotypes.
Results
The Illumina 1 M array covers all of the SNPs on the Illumina
550 K array. We started with all SAGE subjects genotyped on the
Illumina 1 M array and extracted the 545,966 SNPs that are
present on the Illumina 550 K SNPs. We used these Illumina
550 K SNPs to impute to the full Illumina 1 M array. We imputed
262,864 autosomal SNPs in 2597 European Americans (EA), and
304,425 autosomal SNPs in 1264 African Americans (AA). We
compared imputed SNPs to the genotyping results from the
Illumina 1 M array. The remaining SNPs could not be evaluated
due to the absence of those SNPs in either the Illumina 1 M array
or reference panel.
The imputation results are given in Table 2. The mean IQS is
lower than the mean accuracy in both EA and AA. There are
cases where IQS is negative, indicating that imputation did worse
than chance in assigning genotypes. In this situation, 95% of the
minor allele frequencies lie between 0 and 0.058, 95% of the
chance agreement rates lie between 0.78 and 1, and the
imputation accuracy is below chance agreement with 95% of the
Imputation Quality Score
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values between 0.81 and 1. These are strong examples of how
imputation accuracy can be misleading when ‘‘chance’’ contrib-
utes so strongly to the proportion of agreement.
A second notable result is that the quality of imputation in AA is
markedly lower than in EA. This is seen in the decreased efficiency
by nearly ten percentage points, and decrease in mean IQS by
nearly twelve percentage points. This is likely due to two factors.
First, African Americans have more diverse haplotypes and more
uncommon alleles. Second, there is non-negligible difference
between African Americans and the YRI reference panel, which
was clearly reflected by Eigenstrat population structure analysis
[17]. Interestingly, imputation accuracy is nearly the same for EA
as for AA, again highlighting how imputation accuracy can
overestimate the quality of imputation.
The relationship between IQS and imputation accuracy with
respect to minor allele frequency is seen in Figure 1. Although
imputation accuracy increases with decreased minor allele
frequency, IQS drops dramatically with decreased minor allele
frequency. Because it is known that low minor allele frequency
decreases the quality of imputation, many studies drop SNPs with
minor allele frequency less than 1%. According to this plot, this
practice would still retain SNPs with an average IQS score of 88%,
and would eliminate some well-imputed SNPs.
We then evaluated the effectiveness of IQS in the situation
where cases and controls are genotyped on different platforms. We
randomly divided the SAGE data into two subgroups labeled
‘‘cases’’ and ‘‘controls’’. In ‘‘cases’’, original genotypes were
retained for SNPs on the Illumina 550 K array; and then
imputation was performed to obtain the full Illumina 1 M array.
In ‘‘controls’’, original genotypes were retained for all SNPs on the
Illumina 1 M array. This process is equivalent to combining cases
genotyped by the Illumina 550 K array and controls genotyped by
the Illumina 1 M array.
We tested genetic association of all the 1 M SNPs with the cases
and controls. A Quantile-Quantile Plot (Q-Q plot) is shown in
Figure 2. By comparing the distribution of observed P values
against the theoretical model distribution of expected P values, Q-
Q plots are used in genome wide association studies to assess the
inflation of false positive rates [19]. In randomized data without
type I error arising from population stratification or some other
artifact, the Q-Q plot should be a 45 degree line. To ensure that
our random division of the data did not result in population
stratification, we constructed a Q-Q plot based on the true
genotypes, which was normal as expected (l=1.03) (Fig. 2A).
However, the Q-Q plot of imputed SNPs compared to genotyped
SNPs is greatly distorted (l=1.15), suggesting that combining
imputed SNPs with genotyped SNPs without other quality control
Table 2. Summary of evaluation measures for European
American and African American samples.
Ethnic group
European
Americans
African
Americans
Evaluation Measures No. of imputed SNPs 260908 304425
Imputation Accuracy Efficiency % 94.5 85.1
Mean % 98.8 97.1
Range % 0.0,100.0 0.0,100.0
Inter-quartile % 98.8,99.9 96.3,99.5
Imputation Quality
Score (IQS)
Mean % 90.2 78.3
Range % 29.1,100 27.9,100
Inter-quartile % 90.7,99.2 68.4,94.3
doi:10.1371/journal.pone.0009697.t002
Figure 1. The means of IQS and imputation accuracy within each minor allele frequency interval. IQS adjusts for chance agreement. As
the minor allele frequency approaches 0, the difference between IQS and imputation accuracy increases. The standard deviation is shown for every
other point.
doi:10.1371/journal.pone.0009697.g001
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is problematic (Fig. 2B). Therefore, the observed distortion was
due to imputation error and the statistically skewed SNPs (Fig. 2B)
are false positives. We then filtered the imputed data by removing
all SNPs with IQS#0.9, retaining 76% of the imputed SNPs, and
dramatically improving the Q-Q Plot (l=1.04) (Fig. 2C). The Q-
Q plot remained grossly distorted even when the filter was
changed to an imputation accuracy of .99%, retaining 72% of
the SNPs, although l improved to 1.05 (Fig. 2D). Although this is
a very strict value for imputation accuracy, the Q-Q plot clearly
shows there is significant type I error.
A more practical way of evaluating this approach is to look at
the false positive rate. Specifically, although no SNPs are
associated with case/control status based on the true genotypes,
there were 4016 imputed SNPs that reach genome-wide
significance (p,561028). The IQS filter .0.9 eliminated all the
false positive SNPs, but the imputation accuracy filter .0.99 still
retained 759 false-positive SNPs. Based on these results, IQS is
better for discriminating between well-imputed SNPs and poorly-
imputed SNPs.
Although IQS can serve as an effective filter to minimize the use
of poorly-imputed SNPs, the computation of IQS requires a
sample that was both imputed and genotyped for the SNPs of
interest. This is impractical in most situations. A secondary goal of
this paper is to determine whether there are ways to evaluate
imputation quality without knowing the true genotypes.
The two common methods for filtering imputed data are to
combine a minor allele frequency threshold with either the imputed
information score .0.3,0.5 (PROPER_INFO in SNPTEST)
[10,18,20,21,22] or the variance ratio .0.3 (rsq_hat in MACH)
[7,10,20,21,22,23,24,25]. We calculated these two statistics for our
Figure 2. The Q-Q plots based on randomly dividing data into cases and controls. Samples were divided randomly into cases and controls.
(A) All Illumina 1 M SNPs are directly genotyped indicating there is no population stratification or other non-random factors in cases and controls. (B)
Cases were genotyped on the Illumina 550 K array and the remaining Illumina 1 M SNPs were imputed. (C) An IQS filter (IQS.0.9) was applied,
retaining 92% of the SNPs. (D) An imputation accuracy filter (.0.99) was applied, retaining 91% of the SNPs.
doi:10.1371/journal.pone.0009697.g002
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data and compared these filters to IQS (Table 3). After filtering by
these statistics, the type I error inflation decreases. In the AA
sample, IQS also acts as an effective filter and can be cautiously
approximated by a combination of MAF and either the imputed
information score or the variance ratio (Table S1). Unfortunately,
even in the most conservative situation, over three thousand false
positives remain. Therefore this is an ineffective approach for
filtering poorly-imputed SNPs.
Filtering on MAF differences between the Hapmap and the
study genotypes is another possible approach to control false
positives. In Table 3 and Supplementary Table S1, we provided
results filtered by MAF difference at 0.01, 0.1 and 0.2 for
European Americans and African Americans, respectively.
Filtering by MAF difference of 0.01 resulted in a reduction of
false positives, but retained less than 25% of the SNPs. In contrast,
filtering with a MAF difference of 0.1 or 0.2 retained many false
positives.
A second method for using IQS without directly genotyping
would be to develop a database of common imputations in
common populations that records IQS scores for each SNP. To
test the practicality of this approach, we randomly divided the data
into two groups and tested the robustness of the IQS score for the
SNPs imputed from the Illumina 550 K array to the Illumina 1 M
array in both EA and AA. Because small changes in the
denominator of IQS (1-Pc) will dramatically affect the value of
the statistic when MAF is small, we included only SNPs with
MAF.0.01. Figure 3 plots the IQS scores in both populations.
The correlation in EA is 0.99519 and the correlation in AA is
0.99020, indicating that IQS is robust for the same imputation in a
relatively homogeneous population.
We further tested whether the set of hard-to-impute SNPs
compiled from the first group can be used to filter the imputed
data in the second group. We applied a similar procedure as in
Figure 1. We randomly divided the second group into cases and
controls. Cases were genotyped on the Illumina 550 K array and
the remaining Illumina 1 M SNPs were imputed. Controls were
genotyped on the Illumina 1 M array. Figure 4 shows that the QQ
plot can be adjusted to normal by IQS calculated from the first
group. This implies that the development of a database of IQS
scores for standard imputations would allow researchers to use
data genotyped on different platforms and filter out potential false
positives.
In order to confirm these results in a different dataset, we
replicated the study in European American subjects genotyped on
two different platforms, Affymetrix 5.0 array and Illumina 550 K
array. All subjects were controls from the National Institute of
Mental Health Center for Collaborative Genetic Studies on
Mental Disorders. We randomly divided about 400 individuals
into two subgroups labeled ‘‘cases’’ and ‘‘controls’’ in a similar
manner as above. ‘‘Cases’’ were genotyped by the Affymetrix 5.0
array and ‘‘controls’’ were genotyped by the Illumina 550 K array.
In the replication, we also expanded our investigation to include
those SNPs that were not genotyped in either array, but were
imputed from their respective arrays. In fact, we had genotype
data from both platforms. No genome wide significant SNPs were
found. Therefore, if there were any significant SNPs in this
simulation, they should be false positives. The result was similar
with inflation of Type I error that is effectively filtered by IQS,
whereas filtering by MAF and either the imputed information
score or the variance ratio continue to have many false positive
values (Table S2).
Discussion
There are two situations in which imputation is avoided[18]: (1)
SNPs with low minor allele frequency and (2) cases and controls
genotyped on different platforms. The statistics previously used for
measuring the accuracy of imputation are inadequate for
evaluating the quality of imputation due to their dependence on
marginal SNP frequency. Specifically, imputation accuracy, a
measure of the concordance rate between the imputed and
observed genotypes for each SNP, dramatically over-estimates
reliability when minor allele frequencies are low and does not
address the inflation of false positive rates arising from imputation
error due to random agreement. We developed IQS to more
precisely estimate imputation error, effectively filtering imputation
error in these two problematic situations. We showed that IQS is a
more appropriate measure to evaluate imputation reliability
because it adjusts for ‘‘chance’’ agreement, and filtering by IQS
eliminates the inflation of the false positive rate arising from
imputation error.
It is important to note that the traditional genome inflation
factor l is not an ideal indicator of potential problems related to
imputation quality. In our studies, we noticed that l is not
dramatically different from 1, in contrast to the extent that the Q-
Q plot is distorted (Fig. 2B D). The reason is that l reflects
systematic inflation on all SNPs while the distortion of the Q-Q
plot in our studies is due to a small number of poorly-imputed
SNPs. However, problems with this limited number of SNPs (less
than 0.5% of total SNPs) can be dramatic and lead to pronounced
false positive P values that exceed genome wide significance.
We also would like to emphasize that we are dealing with the
extreme situation when cases and controls are genotyped on
different platforms. The elevated false positive rates are not
explicitly reported in the literature, as most groups do not have this
problem because of the study design. But many groups have
noticed it. In a recent paper by de Bakker[18], the author noted
Table 3. Comparison of empirical evaluations of imputation
quality to IQS in European Americans.
Minor Allele
frequency
False positives n
(retained %) .0.01 .0.05 .0.10
IQS .0.9 0 (89.47%) 0 (83.90%) 0 (72.92%)
No filter 3120 (96.63%) 2331 (89.48%) 1775 (77.47%)
Proper_info .0.5 3093 (96.62%) 2329 (89.48%) 1775 (77.47%)
Proper_info .0.7 2726 (96.32%) 2080 (89.28%) 1571 (77.31%)
Proper_info .0.9 1392 (94.16%) 1032 (87.67%) 805 (76.06%)
Variance Ratio .0.3 1869 (96.22%) 1526 (89.27%) 1234 (77.33%)
Variance Ratio .0.5 1226 (95.65%) 928 (88.89%) 770 (77.04%)
Variance Ratio .0.7 789 (94.57%) 514 (88.12%) 390 (76.47%)
Variance Ratio .0.9 498 (90.40%) 253 (85.00%) 153 (74.14%)
MAF difference ,0.01 267 (22.89%) 120 (19.63%) 76 (15.60%)
MAF difference ,0.1 2516 (95.11%) 1739 (87.97%) 1191 (75.94%)
MAF difference ,0.2 2952 (96.57%) 2168 (89.42%) 1615 (77.38%)
The sample is based on 2,597 European Americans that were randomized to
cases and controls. Cases used genotypes from the Illumina 550 K platform and
were imputed to the 1 M platform and controls were genotyped on the 1 M
platform. Genome-wide significance is set as p,561028. There were 792,563
SNPs available. False positives refer to the absolute number of SNPs that
reached genome-wide significance despite the filter. The retained percentage is
the proportion of SNPs that passed the filter.
doi:10.1371/journal.pone.0009697.t003
Imputation Quality Score
PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9697
Imputation Quality Score
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9697
‘‘the dangers of combining cases genotyped on one platform and
controls genotyped on another’’ (Page 124). In the GENEVA
consortium, there is a consensus that genotypes imputed from one
array should not be combined with imputed genotypes from
another array.
The reasons for the false positives are very complicated. Among
the 4016 genome wide significant SNPs, most of them have low R
square with other available SNPs. It is difficult to correctly assign
their values based on related haplotypes, and they therefore tend
to receive the allele frequency from the reference panel.
Filtering by the difference between the reference and the
estimated minor allele frequency can effectively remove some
genome wide significant SNPs. Of the 4016 genome wide falsely-
significant SNPs, 3120 (77.7%) SNPs are removed by removing
those SNPs whose minor allele frequency difference is greater than
0.01.However, there are still 832 (21% of the 4016 SNPs) that have
passed the filter. Most of the 832 remaining SNPs share one
character: they tend to have very low minor allele frequency (MAF
median = 0.00096). Imputation tends to over-assign the major
genotype to the imputed SNPs, resulting in different allele frequency
Figure 4. A database of IQS can be used to filter poorly-imputed SNPs. The set of hard-to-impute SNPs compiled from one dataset can be
used to filter the imputed data in another dataset. (A) Cases were European Americans genotyped on the Illumina 550 K array and the remaining
Illumina 1 M SNPs were imputed. Controls were European Americans genotyped on the Illumina 1 M array. The QQ plot was shown for the 790,965
available SNPs. (B) An IQS filter (IQS.0.9) was applied, retaining 92% of the SNPs. IQS was calculated from an independent dataset. (C) A similar QQ
plot for African Americans. Cases were genotyped on the Illumina 550 K array and the remaining Illumina 1 M SNPs were imputed. Controls were
genotyped on the Illumina 1 M array. The QQ plot was shown for the 836,993 available SNPs. (D) An IQS filter (IQS.0.9) was applied, retaining 78% of
the SNPs. IQS was calculated from an independent dataset.
doi:10.1371/journal.pone.0009697.g004
Figure 3. Evaluation of the robustness of IQS score. European Americans (A) and African Americans(B) datasets were split in half and Illumina
550 K SNPs were imputed to Illumina 1 M SNPs. IQS score for the two halves of the data were plotted against each other. SNPs with minor allele
frequency less than 0.01 were excluded to avoid zero in the denominator.
doi:10.1371/journal.pone.0009697.g003
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and therefore inflating the P value. However, to filter by MAF
difference at 0.01 is not an acceptable option. Most SNPs are
correctly predicted even if the minor allele frequency is different.
When we tried to remove all SNPs whose minor allele frequency
difference was greater than 0.01, 583,456 of the total 788,944
available SNPs (74%) were removed. Most of these SNPs were
correctly predicted even if minor allele frequency was different. This
is because imputation does not assign predicted genotype based on
minor allele frequency, but rather on haplotype modeling.
The typical methods for filtering poorly-imputed SNPs are using
either the variance ratio or the imputed information score combined
with minor allele frequency. Imputation quality is especially
important in a study that combines genotypes from different
platforms. Therefore, we increased our thresholds for variance ratio
and the imputed information score in Table 3, and in Supplemen-
tary Tables S1 and S2. But these measures were ineffective in this
extreme situation. However, IQS may be used as an effective filter
to combine data genotyped on different platforms.
Because IQS requires direct genotyping for evaluation, it is not a
practical statistic for directly evaluating imputation in the case
where imputation is used to screen for associations as a proxy for
genotyping. However, IQS was shown to be a robust measure of
imputation for specific imputations (from one standard platform to
another) and within a broad population (tested in both EA and AA).
Generally speaking, different populations have different linkage
disequilibrium structures and different allele frequencies that lead
to different IQS values. A mixture of different populations will
make the IQS sensitive to the ratio of population mixture.
Therefore, as in general association studies, a mixture of different
populations should be avoided. However, African Americans have
a unique and relatively stable genetic structure. The IQS score
from African Americans is stable in our study and is useful to filter
out poorly imputed SNPs.
Based on this theory, a database can be constructed and used to
filter future imputations and to avoid false positive associations. In
order to advance the development of this database, we have posted
IQS scores for imputation from Illumina 550 K to Illumina 1 M for
CEPH on the website of the NIMH Center (http://www.
nimhgenetics.org/). We envision this as a dynamic database to be
updated when new datasets include subjects genotyped on multiple
platforms. We will further provide IQS scores for various array
combinations when the genotype data of 6,000 controls typed on
both the Affymetrix 6.0 and Illumina 1 M array are available in the
near future [26]. The future database will include IQS scores for the
following imputations: (1) from Affymetrix 6.0 to Illumina 1 M, (2)
from Illumina 1 M to Affymetrix 6.0, (3) from Illumina 300 K to
Affymetrix 6.0 plus Illumina 1 M, (4) from Illumina 550 K to
Affymetrix 6.0 plus Illumina 1 M, and (5) from Affymetrix 5.0 to
Affymetrix 6.0 plus Illumina 1 M. Although genotyping will be
ultimately required to confirm associations, using IQS as a filter will
decrease the amount of false positive findings that arise, making
follow up of positive associations practical.
As genome wide association studies move toward rare variants,
over-estimation of the quality of imputation due to chance
concordance of uncommon alleles will be more common. In
addition, imputation will and should be used to analyze increasingly
complex data structures. IQS can be used as an accurate evaluation
of imputation quality enabling researchers to examine low allele
frequencies and complex data structures.
Supporting Information
Table S1 Comparison of empirical evaluations of imputation
quality to IQS in African Americans. The sample is based on
1,264 African Americans that were randomized to cases and
controls. Cases used genotypes from the Illumina 550K platform
and were imputed to the 1M platform and controls were
genotyped on the 1 M platform. Genome-wide significance is set
as p,5E-8. There were 837,001 SNPs available. False positives
refer to the absolute number of SNPs that reached genome-wide
significance despite the filter. The retained percentage is the
proportion of SNPs that passed the filter.
Found at: doi:10.1371/journal.pone.0009697.s001 (0.04 MB
DOC)
Table S2 Comparison of empirical evaluations of imputation
quality to IQS when combining Affymetrix 5.0 and Illumina
550 K SNPs. The sample is based on 418 healthy European
Americans from the NIMH Repository. Cases were genotyped on
the Affymetrix 5.0 platform and were imputed to the Illumina 550
platform and controls were genotyped on the Illumina 550
platform and imputed to the Affymetrix 5.0 platform. Genome-
wide significance is set as p,5E-8. There were 2,553,465 SNPs
available (including Hapmap SNPs). False positives refer to the
absolute number of SNPs that reached genome-wide significance
despite the filter. The retained percentage is the proportion of
SNPs that passed the filter.
Found at: doi:10.1371/journal.pone.0009697.s002 (0.04 MB
DOC)
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